Money is flooding into exchange- traded funds focused on health care at the fastest rate in at least six years, driven by booming biotechnology and pharmaceutical sectors bringing new products to market.
The price of Gilead Sciences Inc.’s $1,000-a-day hepatitis C pill is keeping state-run Medicaid programs from making it available to many of the people who are most likely to be infected with the disease.
John C. Martin, the chief executive officer of Gilead Sciences Inc., has become a billionaire on the prospects of a powerful new hepatitis C drug that’s attracting scrutiny from payers and activists over its $1,000 per pill price tag.
AbbVie Inc.’s combination hepatitis C therapy cured almost all patients in a late-stage study, moving the company closer to marketing a treatment that will compete with Gilead Sciences Inc. and Bristol-Myers Squibb Co.
Visa Inc. and MasterCard Inc., which processed $7.4 trillion in purchases last year, are among leading payments networks that devote thousands of words in filings to every perceived threat to their business. “Bitcoin” isn’t one of them.
Gemalto NV fell the most in more than three years after Visa Inc., owner of the biggest bank-card network, said it’s offering cheaper alternatives to the company’s technology for payments using mobile phones.
Incyte Corp., the cancer-drug maker whose shares have almost tripled since August, has unrecognized value in its experimental medicines that may fuel more growth than investors expect, its new chief executive officer said.
Gilead Sciences Inc., the world’s largest maker of HIV medicines, said insurers have responded favorably over coverage of its new hepatitis C drug, which has a price tag of $84,000 for a 12-week course of treatment.